Indoco Remedies Limited has informed the Exchange about Update on the Company's testing facility at Chhatrapati Sambaji Nagar (Aurangabad)
INDOCO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.7 pts more than Nifty Microcap 250 and 1.5 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Indoco Remedies received a Pre-Approval Inspection from the U.S. FDA at its testing facility in Chhatrapati Sambaji Nagar (Aurangabad) from April 8-10, 2026. The inspection concluded with zero Form 483 observations, which is the best possible outcome. A Form 483 is issued when FDA investigators find conditions that may violate the Food, Drug, and Cosmetic Act. Zero observations indicate the facility meets all regulatory standards and is ready for product approvals. This suggests the company may be seeking approval to manufacture or supply products to the U.S. market.
This is a strong positive development for shareholders as a zero 483 outcome removes a key regulatory hurdle. It enhances the company's credibility with global regulators and may open doors to U.S. market opportunities, potentially boosting future revenue from exports.